Hepatobiliary surgery and nutrition最新文献

{"title":"Anatomical or non-anatomical resections for hepatocellular carcinoma: a never-ending debate.","authors":"Giammauro Berardi, Edoardo Maria Muttillo, Marco Colasanti, Paolo Mercantini, Giuseppe Maria Ettorre","doi":"10.21037/hbsn-2025-49","DOIUrl":"https://doi.org/10.21037/hbsn-2025-49","url":null,"abstract":"","PeriodicalId":12878,"journal":{"name":"Hepatobiliary surgery and nutrition","volume":"14 2","pages":"342-344"},"PeriodicalIF":6.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Xalnesiran with or without an immunomodulator in chronic hepatitis B: still a challenge in functional cure.","authors":"Qiao Tang, Yunling Xue, Peng Hu","doi":"10.21037/hbsn-2025-92","DOIUrl":"https://doi.org/10.21037/hbsn-2025-92","url":null,"abstract":"","PeriodicalId":12878,"journal":{"name":"Hepatobiliary surgery and nutrition","volume":"14 2","pages":"348-350"},"PeriodicalIF":6.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057499/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-chemotherapy liver atrophy does not impact the outcome after hepatectomy performed under a parenchymal-sparing approach.","authors":"Matteo Donadon, Virginia Laurenti, Simone Famularo, Benedetta Sargenti, Bruno Branciforte, Pio Corleone, Lucio Urbani, Guido Torzilli","doi":"10.21037/hbsn-23-642","DOIUrl":"https://doi.org/10.21037/hbsn-23-642","url":null,"abstract":"<p><strong>Background: </strong>Major hepatectomy in patients with colorectal liver metastases (CLM) and post-chemotherapy liver atrophy is associated with increased complications. Whether the performance of parenchymal-sparing hepatectomy (PSH) in those patients can be safer is unknown.</p><p><strong>Methods: </strong>Databases at two institutions were queried, and 74 CLM patients who underwent preoperative chemotherapy and curative PSH were reviewed. Pre- and post-chemotherapy total liver volumes (TLVs) were computed with Synapse 3D software, and the degree of atrophy was calculated as the difference in percentage. The cut-off value for significant degree of atrophy was set at 10%. Risk factors for post-chemotherapy liver atrophy were assessed using logistic regression, while multivariate analysis was computed to identify risk factors for postoperative complications.</p><p><strong>Results: </strong>With median CLM number of 6 (range, 1-20) and median CLM size of 3.3 cm (range, 1-14 cm), all patients underwent complex PSH. The 90-day mortality was 1%; Clavien-Dindo >2 complications occurred in 17%, with 6 (8%) post-hepatectomy liver failure (PHLF) events; 33 (45%) patients experienced ≥10% post-chemotherapy atrophy, of which pre-chemotherapy TLV was the only independent predictor [odds ratio (OR) =1.741; 95% confidence interval (CI): 1.120-2.386; P=0.02]. At multivariate analysis, none of the investigated variables showed significant association with PHLF or complications, which were not significantly increased in patients who experienced liver atrophy.</p><p><strong>Conclusions: </strong>As opposed to what observed after major hepatic resections, a significant degree of post-chemotherapy liver atrophy does not represent a source of postoperative complications in CLM patients undergoing PSH.</p>","PeriodicalId":12878,"journal":{"name":"Hepatobiliary surgery and nutrition","volume":"14 2","pages":"181-193"},"PeriodicalIF":6.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057497/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and longitudinal effects on mortality associated with spectrum of alcohol intake in steatotic liver disease: a United States population study.","authors":"Christen Ong, Nicole Tang, Shyna Gunalan, Margaret Teng, Benjamin Koh, Douglas Chee, Jia Hong Koh, Daniel Tung, Nicholas Syn, Dan Nakano, Anand Kulkarni, Michelle Law, Takao Miwa, Hirokazu Takahashi, Mark Muthiah, Karn Wijarnpreecha, George Ioannou, Cheng Han Ng, Daniel Q Huang, Mazen Noureddin","doi":"10.21037/hbsn-24-51","DOIUrl":"https://doi.org/10.21037/hbsn-24-51","url":null,"abstract":"<p><strong>Background: </strong>The recently introduced set of terminologies defining categories of steatotic liver disease (SLD) includes metabolic dysfunction-associated SLD (MASLD), alcohol-associated liver disease (ALD), and metabolic dysfunction associated steatotic liver disease and increased alcohol intake (MetALD). The present retrospective cohort study examines clinical characteristics, prevalence, and mortality risk across alcoholic intake spectrum in SLD individuals.</p><p><strong>Methods: </strong>Data between 1999 to 2018 were extracted from National Health and Nutrition Examination Survey registries and analysed. Population baseline characteristics were evaluated across classifications of SLD. SLD was confirmed using either fatty liver index (FLI) or United States FLI (US-FLI). Multivariate analyses were used to study mortality-related outcomes.</p><p><strong>Results: </strong>The 20,510 individuals with SLD included were classified into MASLD predominant (69.00%), MetALD (18.77%), and ALD predominant (12.23%) groups. Temporal analysis revealed significant decreases in MASLD prevalence in the SLD population from 1999-2018 in general [average annual percentage change (AAPC) -4.802%, P=0.001], as well as in females, Mexican Americans, and Non-Hispanic Blacks. MetALD prevalence in the SLD population increased from 1999-2018 in general (AAPC +1.635%, P<0.001), and in males, females, Mexican Americans, Non-Hispanic Blacks and other ethnicities. No significant change in ALD prevalence was found. Compared to MASLD predominant individuals, ALD predominant individuals had higher risks of all-cause [hazard ratio (HR): 1.189, 95% confidence interval (CI): 1.026 to 1.378, P=0.02] and cancer-related mortality (subdistribution HR: 1.277, 95% CI: 1.032 to 1.579, P=0.02). No significant difference was observed for all-cause, cancer-related, or cardiovascular disease (CVD)-related mortality in MetALD and CVD-related mortality in ALD predominant individuals, relative to MASLD predominant individuals.</p><p><strong>Conclusions: </strong>ALD predominant patients have higher all-cause and cancer-related mortality risks than MASLD predominant patients but not CVD-related mortality. SLD is highly heterogeneous in clinical characteristics, prevalence, and mortality risks which healthcare professionals must account for to avert adverse health outcomes.</p>","PeriodicalId":12878,"journal":{"name":"Hepatobiliary surgery and nutrition","volume":"14 2","pages":"222-232"},"PeriodicalIF":6.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of the gut microbiome and metabolites on biliary tract cancer: insight from a bidirectional two-sample Mendelian randomization study.","authors":"Wen-Bo Zou, Jia-Ni Liu, Yuan-Shu Lian, Gao Huang","doi":"10.21037/hbsn-2024-750","DOIUrl":"https://doi.org/10.21037/hbsn-2024-750","url":null,"abstract":"","PeriodicalId":12878,"journal":{"name":"Hepatobiliary surgery and nutrition","volume":"14 2","pages":"298-300"},"PeriodicalIF":6.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical advantages and efficacy of sleeve gastrectomy in the treatment of non-alcoholic fatty liver disease.","authors":"Wenbo Wang, Yaoquan Cao, Liyong Zhu","doi":"10.21037/hbsn-2025-2","DOIUrl":"https://doi.org/10.21037/hbsn-2025-2","url":null,"abstract":"","PeriodicalId":12878,"journal":{"name":"Hepatobiliary surgery and nutrition","volume":"14 2","pages":"329-331"},"PeriodicalIF":6.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endothelial glycocalyx damage marker syndecan-1 during hypothermic oxygenated machine perfusion of donor grafts facilitates prediction of early allograft dysfunction after liver transplantation.","authors":"Laurin Rauter, Dagmar Kollmann, Judith Schiefer, Marija Spasic, Pierre Raeven, Jule Dingfelder, David Pereyra, David M Baron, Effimia Pompouridou, Thomas Soliman, Gabriela Berlakovich, Georg Györi","doi":"10.21037/hbsn-24-33","DOIUrl":"https://doi.org/10.21037/hbsn-24-33","url":null,"abstract":"<p><strong>Background: </strong>Ischemia reperfusion injury (IRI) is a major contributing factor to organ damage in liver transplantation (LT) impacting donor organ quality and patient survival. IRI-inflicted graft injury can be reduced by using hypothermic oxygenated machine perfusion (HOPE) as a preservation strategy instead of static cold storage (SCS). The endothelial glycocalyx is highly sensitive to IRI and its degradation during graft preservation and reperfusion was previously associated with inferior postoperative outcome after LT. Here, we aimed to measure glycocalyx degradation during and after HOPE in order to evaluate its potential for viability-assessment during machine perfusion and outcome prediction in patients undergoing LT.</p><p><strong>Methods: </strong>Glycocalyx degradation was quantified via enzyme-linked immunoassay (ELISA) for its main component syndecan-1 (Sdc-1) in serum of 40 patients undergoing LT after HOPE. In addition, Sdc-1 was evaluated at multiple time points during HOPE. Patients were followed up for 3.5 years to assess postoperative complications including morbidity, the development of early allograft dysfunction (EAD) and graft survival.</p><p><strong>Results: </strong>Liver grafts which later developed EAD showed significantly higher Sdc-1 concentrations after 60 min of HOPE compared to grafts exhibiting normal postoperative function (P=0.02). Receiver operating characteristic analysis revealed a strong predictive potential with an area under the curve of 0.73. A cut-off at 808 ng/mL Sdc-1 at 60 min of HOPE allowed identification of a high-risk group with an incidence of EAD of 66.7%. Sdc-1 concentrations increased during all types of HOPE but were significantly higher in HOPE versus dual HOPE (D-HOPE) after 120 min of perfusion (P=0.02).</p><p><strong>Conclusions: </strong>Sdc-1 evaluated at 60 min during HOPE allows prediction of EAD after LT. Accordingly, Sdc-1 should be considered a potential additional biomarker for viability assessment during HOPE.</p>","PeriodicalId":12878,"journal":{"name":"Hepatobiliary surgery and nutrition","volume":"14 2","pages":"233-245"},"PeriodicalIF":6.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrence after neoadjuvant therapy for pancreatic cancer: same challenges, new opportunities.","authors":"Taylor Neilson, Jordan M Cloyd","doi":"10.21037/hbsn-2025-96","DOIUrl":"https://doi.org/10.21037/hbsn-2025-96","url":null,"abstract":"","PeriodicalId":12878,"journal":{"name":"Hepatobiliary surgery and nutrition","volume":"14 2","pages":"308-310"},"PeriodicalIF":6.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057488/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcopenia's increasingly vital role in liver cancer.","authors":"Xuelei Xu, Xinwei Pan, Hongshuang Chen, Yan Zhang, Weinan Liu","doi":"10.21037/hbsn-2025-155","DOIUrl":"https://doi.org/10.21037/hbsn-2025-155","url":null,"abstract":"","PeriodicalId":12878,"journal":{"name":"Hepatobiliary surgery and nutrition","volume":"14 2","pages":"326-328"},"PeriodicalIF":6.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovations in liver organoids: the role of 3D bioprinting in creating functional organoids.","authors":"Kai Zhang, Huayu Yang","doi":"10.21037/hbsn-2025-154","DOIUrl":"https://doi.org/10.21037/hbsn-2025-154","url":null,"abstract":"","PeriodicalId":12878,"journal":{"name":"Hepatobiliary surgery and nutrition","volume":"14 2","pages":"322-325"},"PeriodicalIF":6.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}